Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

Published:2015-02-19 Issue:8 Volume:125 Page:1333-1338
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Holtan Shernan G.¹,DeFor Todd E.²,Lazaryan Aleksandr¹,Bejanyan Nelli¹,Arora Mukta¹,Brunstein Claudio G.¹,Blazar Bruce R.¹,MacMillan Margaret L.¹,Weisdorf Daniel J.¹

Affiliation:

1. Blood and Marrow Transplant Program, and

2. Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Abstract

Key Points GRFS is a new composite end point useful for comparing HCT techniques and represents ideal post-HCT recovery. In our cohort of 907 allogeneic HCT recipients, 1-year GRFS was 31%, with best outcomes in recipients of marrow from matched sibling donors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/8/1333/1387499/1333.pdf

Reference21 articles.

1. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.;Sehn;J Clin Oncol,1999

2. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.;Soiffer;Blood,2011

3. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.;Alyea;Biol Blood Marrow Transplant,2002

4. Use of composite endpoints in clinical trials.;Sankoh;Stat Med,2014

5. Bolanos-Meade J Koreth J Reshef R A multi-center phase II trial randomizing novel approaches for graft-versus-host disease prevention compared to contemporary controls (1203). Available at: https://clinicaltrials.gov/ct2/show/NCT02208037. Accessed January 19, 2015

Cited by 377 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of melphalan dose in patients with myelodysplastic syndrome undergoing allogeneic transplantation with reduced-intensity conditioning;Transplantation and Cellular Therapy;2024-02

2. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide;Transplantation and Cellular Therapy;2024-02

3. Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations;Transplantation and Cellular Therapy;2024-02

4. reduced Cytokine Release Syndrome and improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplant;Transplantation and Cellular Therapy;2024-01

5. Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant;JAMA Oncology;2023-12-28